Concurrent Investment Advisors LLC Purchases 1,438 Shares of Becton, Dickinson and Company (NYSE:BDX)

Concurrent Investment Advisors LLC lifted its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 10,750 shares of the medical instruments supplier’s stock after acquiring an additional 1,438 shares during the quarter. Concurrent Investment Advisors LLC’s holdings in Becton, Dickinson and Company were worth $2,439,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Brighton Jones LLC increased its position in shares of Becton, Dickinson and Company by 98.2% during the fourth quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares during the period. E. Ohman J or Asset Management AB increased its position in shares of Becton, Dickinson and Company by 13.4% during the fourth quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock worth $39,951,000 after acquiring an additional 20,859 shares during the period. Arete Wealth Advisors LLC purchased a new position in Becton, Dickinson and Company during the third quarter valued at approximately $767,000. Busey Bank increased its holdings in Becton, Dickinson and Company by 3.8% during the fourth quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after buying an additional 2,399 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Becton, Dickinson and Company by 79.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after buying an additional 1,317,723 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Piper Sandler lifted their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Barclays lifted their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. Finally, StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, February 12th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $278.29.

Becton, Dickinson and Company Trading Down 0.2 %

NYSE:BDX opened at $227.54 on Friday. The company has a market capitalization of $65.34 billion, a P/E ratio of 37.80, a PEG ratio of 1.63 and a beta of 0.40. The firm has a fifty day simple moving average of $232.90 and a 200-day simple moving average of $233.29. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, equities research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. Becton, Dickinson and Company’s payout ratio is 69.10%.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total transaction of $185,180.00. Following the completion of the sale, the executive vice president now owns 16,201 shares of the company’s stock, valued at $3,807,235. The trade was a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Roland Goette sold 638 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the sale, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,544 shares of company stock valued at $2,370,309. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.